Questcor Pharmaceuticals — Investor Presentation (August 2011)
29 slides from Questcor Pharmaceuticals's investor presentation, Aug 9, 2011
Slide 1: Questcor Investor Presentation August 2011
NASDAQ: QCOR August 2011 Exhibit 99.1 NASDAQ: QCOR August 2011
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performa
Slide 3: Questcor: A biopharmaceutical company for serious, difficult-to-treat conditions
3 Questcor A biopharmaceutical company whose product helps patients with serious, difficult-to-treat medical conditions A biopharmaceutical company whose product helps patients with serious, difficult-to-treat medical conditions
Slide 4: Questcor Overview
Questcor Overview Flagship Product: • Profitable, cash flow positive, $142M* in cash, debt-free • 19 approved indications Key Markets: • Multiple Sclerosis, Nephrotic Syndrome, Infantile Spasms • Combined market opportunity exceeds $1.5 billion Strategy: • Grow Acthar sales in each key market • Deve
Slide 5: History of Acthar
History of Acthar 1950 2000 2010 5 1952 First Approved 1950 1978 MS Indication Added 2000 2001 Questcor Acquires Acthar 2010 Label Modernized 19 Indications 2007 Questcor Changes Strategy 2010
Slide 6: Significant Barriers to Entry
Significant Barriers to Entry
Slide 7: QCOR Strategy – Sell More Acthar
7 QCOR Strategy – Sell More Acthar Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) Lupus Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) Systemic Erythematosus
Slide 8: Acthar and MS
Acthar and MS Inadequate Response to Steroids Poor Venous Access Problematic Steroid Side Effects Acthar when “Steroids are not suitable” *Based on prescriptions written Neurodegenerative disorder Acute treatment for relapses Treatment for 1-2 weeks* $40K-$50K/Rx Inadequate Response to Steroids Poor
Slide 9: MS Sales - Record of Consistent Growth
9 MS Sales - Record of Consistent Growth New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which i
Slide 10: Monthly MS Sales Are Promotion Sensitive
Monthly MS Sales Are Promotion Sensitive 10
Slide 11: MS Trends
11 • Doubled sales force: 38 to 77 sales reps Nov 2010 • Q2-2011 results – Q2-11 new paid Rxs up 147% vs. Q2-10 – MS about 60% of QCOR net sales* • Estimated $110M annualized run-rate* – About 400 prescribers in Q2 – June was a record month • July trends remain solid – Q2 sales level continuing into
Slide 12: Acthar and Nephrotic Syndrome (NS)
12 • Characterized by excessive spilling of protein from the kidneys into the urine (proteinuria) • Can result in end-stage renal disease (ESRD), dialysis, transplant • Significant unmet need – Few treatment options • Treatment for 4-6 months* • $150K-250K/Rx Acthar and Nephrotic Syndrome (NS) *Base
Slide 13: NS Sales – Off to a Good Start
NS Sales – Off to a Good Start New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focu
Slide 14: Estimated total: 20,000-25,000 patients
Estimated total: 20,000-25,000 patients (®& QUESTCOR'
Slide 15: NS Sales
15 • Hired 5 reps to sell Acthar to nephrologists – Initiated sales efforts in early March 2011 – Q1 2011 NS Scripts: 18 • 14 different prescribers – Q2 2011 NS Scripts: 45 • 37 different prescribers • 4-6 month course of therapy creates future vial demand • Expanding the NS selling effort – Planned
Slide 16: NS Phase IV Company Sponsored Study
16 • Treatment Resistant Idiopathic Membranous Nephropathy • Dose response trial – Randomized, double blinded 3 arm study with 2 different dosage regimens of Acthar and placebo – n=84 (approximate), 35 centers (approximate) – Endpoint is reduction of proteinuria • Trial milestones – First patient do
Slide 17: Infantile Spasms
17 • Devastating, refractory form of childhood epilepsy – Very poor developmental outcome if inadequately treated • Not responsive to standard anti-epileptic drugs • Ultra-rare orphan disorder – 1,500 to 2,000 patients annually • Typically occurs in children less than 2 years old • Characterized by
Slide 18: Acthar and IS
18 • FDA approval 10/15/10 • Crisis therapy • Treatment for 2-4 weeks* • In a randomized, single-blinded, controlled study, 87% of patients achieved overall response (no spasms and no hypsarrhythmia) at two weeks versus 29% on prednisone • $100K-$125K/Rx – About half of patients receive drug for fre
Slide 19: IS Sales
• Targeting select institutions – Promotion effort being narrowed as market is maturing – Creates selling time for Acthar reps to target NS • Significant variability in quarterly Rxs • Q2-2011 sales within historic range – Acthar currently used to treat 40-50% of IS patients IS Sales 19 Targeting se
Slide 20: Immediate Acthar Growth Opportunities
20 *Represents estimated net sales market opportunity based on internal company estimates ** Represents approximately 4 times Q1 11 net sales by therapeutic area based on internal company estimates MS NS IS Immediate Acthar Growth Opportunities Build on sales momentum, good market headroom Market si
Slide 21: Total Acthar Sales Force
21 • Specialty Sales Force – Main focus on MS (~80%), 15% on NS, 5% on IS – 77 representatives, 13 regional managers, one national director • Nephrology Sales Force – Focus 100% on Nephrotic Syndrome – 28 representatives, 4 regional managers, one national director • Combined Forces will be calling o
Slide 22: Systemic Lupus Erythematosus (Lupus)
22 • High unmet need • Serious health risk if unsuccessfully treated • Difficult to treat • Multiple on-label indications for Acthar – Exacerbations – Maintenance therapy – Lupus nephritis • Large patient population Systemic Lupus Erythematosus (Lupus) High unmet need Serious health risk if unsucces
Slide 23: Financials
23 Financials Profitable Debt Free Cash Flow Positive Profitable Debt Free Cash Flow Positive
Slide 24: Q2-2011 Financial Results
24 Q2-2011 Financial Results Net Sales ($M) Gross Margin Operating Income ($M) Fully Diluted, GAAP EPS $ 46.0 94% $20.4 $0.21 $28.3 93% $14.3 $0.14 Q2-2011 Q2-2010 Record Sales (up 62%) and Solid Earnings (EPS up 50%) Net Sales ($M) Gross Margin Operating Income ($M) Fully Diluted, GAAP EPS $ 46.0 9
Slide 25: Questcor is Cash Flow Positive
Questcor is Cash Flow Positive Cash / ST Investments Accounts Receivable $142M* $28M 7/29/11 Debt-free balance sheet 25 *After return of $78 million of cash to shareholders through share repurchases. Cash / ST Investments Accounts Receivable $142M* $28M 7/29/11
Slide 26: Share Repurchases
Share Repurchases: 15 Million Shares • 2.2 Million Preferred share buyback • 13.2 Common share buyback • $78 million returned to shareholders in stock buybacks • 62.3 million shares currently outstanding • 4.3 million shares remain on buyback authorization 26 Repurchases significantly improve EPS 2.
Slide 27: Go Forward Plan - Sell More Acthar
27 • Sustain effort and momentum with MS • Expand NS selling effort • Maintain and gradually grow IS sales • Explore Systemic Lupus Erythematosus (Lupus) as next vertical market • Develop other markets for Acthar • No business development efforts planned Go Forward Plan - Sell More Acthar Sustain ef
Slide 28: Investment Highlights
28 Investment Highlights Questcor has good sales momentum Acthar has sustainable competitive advantages Focus on substantial growth in MS and NS New vertical market – Lupus Market sizes have good growth potential Solid financial performance and balance sheet
Slide 29: August 2011
NASDAQ: QCOR August 2011 NASDAQ: QCOR August 2011
Questcor Pharmaceuticals — Investor Presentation (August 2011) on 6ix